论文部分内容阅读
目的 探讨变异型p5 3蛋白表达对人乳腺癌细胞阿霉素抗性及乳腺癌手术前阿霉素化疗疗效的影响。方法 应用免疫组化和图像定量分析技术检测 9例乳腺癌组织中变异型p5 3蛋白含量 ;同时应用琼脂培养MTT法测定乳腺癌细胞对阿霉素的敏感性 ,观察阿霉素化疗对乳腺癌手术前疗效。结果 ⑴ 9例人乳腺癌组织 7例变异型p5 3阳性表达 (阳性率为 77% )。⑵变异型p5 3蛋白表达量 (阳性面积相对比 )与人乳腺癌细胞阿霉素抗药指数 (IC5 0值与 1/10血浆峰值浓度的比值 )呈正相关 (r=0 795 6 ,P <0 0 1)。⑶变异型p5 3蛋白表达量与乳腺癌患者手术前阿霉素化疗疗效积分呈负相关 (r=- 0 86 37,P <0 0 1)。结论 变异型p5 3蛋白表达与乳腺癌细胞对阿霉素抗性及临床化疗疗效相关。
Objective To investigate the effect of variant p5 3 protein expression on the doxorubicin resistance in human breast cancer cells and the chemotherapeutic effect of adriamycin before breast cancer surgery. Methods Immunohistochemistry and quantitative image analysis were used to detect the content of variant p5 3 protein in breast cancer tissues. The sensitivity of adriamycin to doxorubicin in breast cancer cells was determined by agar culture. Preoperative efficacy. Results (1) The positive expression rate of p5 3 was 7 in 9 cases of human breast cancer (positive rate was 77%). (2) The expression of variant p53 protein (positive area ratio) was positively correlated with the doxorubicin resistance index (IC50 value and 1/10 plasma peak concentration ratio) of human breast cancer cells (r = 0 795 6, P < 0 0 1). (3) There was a negative correlation between the expression level of mutant p5 3 protein and the therapeutic effect of adriamycin before operation in breast cancer patients (r = - 0 86 37, P 0 01). Conclusion The expression of variant p53 protein is associated with the resistance to doxorubicin in breast cancer cells and the clinical efficacy of chemotherapy.